Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.